Health Canada lukewarm on Vioxx panel findings.
作者信息
Murray Sally
出版信息
CMAJ. 2005 Aug 16;173(4):350. doi: 10.1503/cmaj.050901.
Abstract
摘要
相似文献
1
Health Canada lukewarm on Vioxx panel findings.
CMAJ. 2005 Aug 16;173(4):350. doi: 10.1503/cmaj.050901.
2
Vioxx doctors wooed by Merck are now its foes.
Wall St J (East Ed). 2006 Mar 10:B1, B3.
3
[Really only Vioxx?].
Med Monatsschr Pharm. 2004 Nov;27(11):361.
4
Rofecoxib (Vioxx) withdrawal: do product monographs adequately inform physicians?
Can Fam Physician. 2005 Feb;51(2):212-3.
5
[The rise and fall of Vioxx: society, values and their choice].
Harefuah. 2004 Nov;143(11):770-1.
6
Learning the value of drugs--is rofecoxib a regulatory success story?
N Engl J Med. 2005 Mar 31;352(13):1285-7. doi: 10.1056/NEJMp048358.
7
Balancing risks and benefits in pain medicine: wither Vioxx.
Pain Med. 2004 Dec;5(4):329-30. doi: 10.1111/j.1526-4637.2004.04056.x.
8
The lessons of Vioxx--drug safety and sales.
N Engl J Med. 2005 Jun 23;352(25):2576-8. doi: 10.1056/NEJMp058136.
9
Vioxx should be allowed back on the market advises expert panel.
CMAJ. 2006 Aug 1;175(3):234. doi: 10.1503/cmaj.060821.
10
Don't throw out the baby with the bathwater!
J Pediatr Hematol Oncol. 2005 Feb;27(2):59-60. doi: 10.1097/01.mph.0000155872.67424.2e.
引用本文的文献
1
Lack of Pharmacokinetic Interaction between Esomeprazole and the Nonsteroidal Anti-Inflammatory Drugs Naproxen and Rofecoxib in Healthy Subjects.
Clin Drug Investig. 2005;25(11):731-40. doi: 10.2165/00044011-200525110-00006.
Zotero 插件